scientificprogram event in Greece September Crown Plaza Hotel Athens Organizers with the scientific collaboration of

Transcription

1 event in Greece A program licensed by the American Society of Clinical Oncology September Crown Plaza Hotel Athens Organizers Θα χορηγηθούν μόρια Συνεχιζόμενης Ιατρικής Εκπαίδευσης (CME - CPD credits) ΔΗΛΩΣΕΙΣ ΣΥΜΜΕΤΟΧΗΣ ΣΤΟ info@scep.gr with the scientific collaboration of scientificprogram

2 02 Επιστημονικό Πρόγραμμα Friday, September 21 st, Welcome and Chair Remarks V. Georgoulias Session 1: Breast Cancer Chairpersons: D. Tryfonopoulos, M. Nikolaou Presenter: S. Kokkali - Abstract ID: 506 Title: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results - Abstract ID: 500 Title: Adjuvantdenosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial Presenter: S. Peroukidis - Abstract ID: LBA1 Title: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score - Abstract ID: 1000 Title: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2 ) advanced breast cancer (ABC): Results from MONALEESA Presenter: F. Stavridi - Abstract ID: 104 Title: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). - Abstract ID: 1005 Title: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study Presenter: E. Moirogiorgou - Abstract ID: LBA1006 Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER - Abstract ID: 1007 Title: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial Discussant: D. Tryfonopoulos Discussion Educational Session: Personalized Care in the Management of Kidney Cancer Chairpersons: G. Samonis, V. Georgoulias Presenter: M. Tsiatas Light lunch Session 2: Malignant Melanoma Chairpersons: D. Bafaloukos, Κ. Kalbakis Presenter: A. Laskarakis - Abstract ID: 108 Title: Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/ KEYNOTE-252 study. - Abstract ID: 9501 Title: Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node Presenter: P. Economopoulou - Abstract ID: 9502 Title: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238) - Abstract ID: 9504 Title: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vsvemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma Discussant: D. Bafaloukos Discussion Session 3: Genitourinary Cancer (Non-Prostate cancer) Chairpersons: A. Nikolaidi, M. Tsiatas Presenter: G. Lainakis - Abstract ID: 4500 Title: Pembrolizumabmonotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accrcc): results from cohort A of KEYNOTE-427 Friday, September 21 st,

3 Friday, September 21 st, Abstract ID: 4511 Title: Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vssunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mrcc) Presenter: E. Lianos - Abstract ID: LBA3 Title: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma - Results of a phase III noninferiority trial - Abstract ID: 4503 Title: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ ) in patients (pts) with metastatic or unresectableurothelial carcinoma (muc) and FGFR alterations (FGFRalt) Discussant: K. Koutsoukos Discussion Coffee Break Session 4: Gastrointestinal (Colorectal) Cancer Chairpersons: N. Ziras, P. Papakostas Presenter: V. Michalaki - Abstract ID: 3505 Title: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mcrc): The VALENTINO study - Abstract ID: 3500 Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC Presenter: N. Tsoukalas - Abstract ID: 3501 Title: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer - Abstract ID: LBA 3503 Title: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE Discussant: G. Papaxoinis Discussion Session 5: Gastrointestinal (Non-Colorectal) Cancer Chairpersons: N. Kentepozidis, O. Katopodis Presenter: T. Bilidas - Abstract ID: LBA4001 Title: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mfolfirinox versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas - Abstract ID: 4004 Title: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211) Presenter: A. Ntokou - Abstract ID: LBA4008 Title: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial - Abstract ID: LBA4002 Title: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial Discussant: A. Karampeazis Discussion Saturday, September 22 nd, Session 6: Lung Cancer (1) Chairpersons: P. Kosmidis, A. Koutsopoulos Presenter: M. Bakogeorgos - Abstract ID: 8503 Title: DREAM: A Phase II study of DuRvalumab with first line chemotherapy in Mesothelioma: First Results - Abstract ID: 8506 Title: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE Presenter: Κ. Rapti - Abstract ID: 8507 Title: Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, 3rd line small cell lung cancer: results from the Phase 2 TRINITY study Friday, September 21 st,

4 Saturday, September 22 nd, Abstract ID: LBA9000 Title: IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-paclitaxel as 1L Therapy in Advanced Squamous NSCLC Presenter: Th. Tegos - Abstract ID: 9001 Title: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study - Abstract ID: 9006 Title: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026 - Abstract ID: LBA4 Title: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study Presenter: E. Res - Abstract ID: 8502 Title: Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection. - Abstract ID: 105 Title: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC) Discussant: N. Katirtzoglou Discussion Session 7: Genitourinary Cancer (Prostate cancer) Chairpersons: Ch. Kourousis, D. Matthaios Presenter: F. Koinis - Abstract ID: 5000 Title: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial - Abstract ID: 5001 Title: Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial Presenter: A. Koulouris - Abstract ID: 5003 Title: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mcrpc): A randomized Phase II trial - Abstract ID: 5007 Title: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mcrpc) Discussant: Z. Zafeiriou Discussion Coffee Break Session 8: Development Therapeutics Clinical Pharmacology / Tumor Biology Chairpersons: F. Zagouri, F. Papageorgiou Presenter: N. Volakakis - Abstract ID: 102 Title: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers - Abstract ID: 3000 Title :ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients (pts) with advanced cancers Presenter: E. Kontopodis - Abstract ID: 3003 Title: Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of AxicabtageneCiloleucel (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma - Abstract ID: 3006 Title: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT Presenter: K. Stouraiti - Abstract ID: Title: Association of high tissue TMB and atezolizumab efficacy across multiple tumor types - Abstract ID: Title: Prospective clinical evaluation of blood-based tumor mutational burden (btmb) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results Discussant: C. Emmanouilides Discussion Saturday, September 22 nd,

5 Saturday, September 22 nd, Light lunch Session 9: Head and Neck Cancer Chairpersons: Ch. Panopoulos, D. Moraitis Presenter: A. Tzovaras Abstract ID: 6000 Title: Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck - Abstract ID:6006 Title: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP) Presenter 2: P. Katsaounis - Abstract ID: 6008 Title: Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) - Abstract ID: 6009 Title: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC) Discussant: A. Argiris Discussion Session 10: Sarcomas Chairpersons: D. Tzanninis, V. Ramfidis Presenter: J. Duran Moreno - Abstract ID: Title: Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ) - Abstract ID: Title: Anlotinib for metastasis soft tissue sarcoma: A randomized, doubleblind, placebo-controlled and multi-centered clinical trial Presenter: I. Alafis - Abstract ID: Title: Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma - Abstract ID: Title: Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial Discussant: S. Kokkali Discussion Coffee Break Session 11: Gynecological Cancer Chairpersons: Ε. Terzakis, D. Trafalis Presenter: S. Stamatopoulou - Abstract ID: 5500 Title: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG Abstract ID: 5505 Title: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study Presenter: I. Syrios - Abstract ID: 5506 Title: Chemotherapy plus or minus bevacizumab for platinum-sensitiveovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17 - Abstract ID: 5508 Title: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab Discussant: Ch. Kourousis Discussion Educational Session: Rational Combinations With an Immuno-Oncology Backbone Chairpersons: K. Baxevanis, V. Georgoulias Presenter: Ν. Pistalmatzian General Discussion Closing Remarks Saturday, September 22 nd,

6 Scientific Cultural Events and Publications T , F , E info@scep.gr w w w.s c e p.g r